We are pleased to announce further funding success to MTCI Investigators from the most recent Call of the  European Commission funded Framework Programme 7 (FP7) initiative. The recently successful FP7 Health application ANGIOPREDICT was co-ordinated by Dr Annette Byrne  [MTCI Funded Investigator & Lecturer, Graduate Entry Programme & Dept of Physiology and Medical Physics, RCSI]. The project  seeks to develop predictive genomic biomarkers methods for combination   bevacizumab (avastin) therapy in metastatic  colorectal cancer  and integrates the combined efforts of nine European partners across academia, industry and clinical research. Total funding awarded was c.6 million Euros with c. 2.9 million going to Irish MTCI partners [ RCSI, UCD, ICORG] & the newly spun-out Irish SME ONCOMARK Ltd.